devTOX DiscoveryTM uses untargeted metabolomics to identify disruptions in metabolism and gain a deeper understanding of the test article mechanism in action.
- Performed with human iPS or ES cells
- Viability dose-response at 8 exposure levels
- Untargeted metabolomics analysis for 3 exposure levels
devTOX DiscoveryTM includes the developmental toxicity prediction found using our devTOX quickPredictTM model, as well as a metabolomic window into disruptions in embryonic metabolism impacted by the test article. This includes the identification of treatment-related changes in hPS cell secretome metabolites.
With devTOX DiscoveryTM, you will advance your understanding of the cellular effects during early development, which can apply to adverse outcome pathways. We can also map to functional pathways related known mechanisms of developmental toxicity.